Co-expression and Impact of Prostate Specific Membrane Antigen and Prostate Specific Antigen in Prostatic Pathologies

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2010 Dec 30

PMID 21189143

Citations 19

Authors

Awatef Ben Jemaa

Yosra Bouraoui

Sataa Sallami

Ahmed Banasr

Nawfel Ben Rais

Latifa Ouertani

Yassin Nouira

Ali Horchani

Ridha Oueslati

Affiliations

Soon will be listed here.

Abstract

Background: The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression.

Methods: The study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression, respectively.

Results: In our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18 and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues (16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA. Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+) expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity.

Conclusion: These data suggest that these markers are regulated differentially and the difference in their expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies the significance of their investigation together in normal and pathologic prostate tissues.

Citing Articles

Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia.

Cao T, Xie F, Shi Y, Xu J, Liu Y, Cui D Int J Biol Sci. 2023; 19(11):3441-3455.

PMID: 37497009 PMC: 10367549. DOI: 10.7150/ijbs.85089.

The Transcriptomic Profiles of and Stratify the Risk of Biochemical Recurrence in Primary Prostate Cancer beyond Clinical Features.

Olczak M, Orzechowska M, Bednarek A, Lipinski M Int J Mol Sci. 2023; 24(9).

PMID: 37176106 PMC: 10179071. DOI: 10.3390/ijms24098399.

Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.

Ionescu C, Aschie M, Matei E, Cozaru G, Deacu M, Mitroi A Biomedicines. 2022; 10(7).

PMID: 35884977 PMC: 9313300. DOI: 10.3390/biomedicines10071672.

KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?.

Koistinen H, Kunnapuu J, Jeltsch M Int J Mol Sci. 2021; 22(24).

PMID: 34948344 PMC: 8704207. DOI: 10.3390/ijms222413545.

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.

Manafi-Farid R, Ranjbar S, Jamshidi Araghi Z, Pilz J, Schweighofer-Zwink G, Pirich C Cancers (Basel). 2021; 13(21).

PMID: 34771523 PMC: 8582501. DOI: 10.3390/cancers13215360.

References

Wright Jr G, Grob B, Haley C, Grossman K, Newhall K, Petrylak D . Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996; 48(2):326-34. DOI: 10.1016/s0090-4295(96)00184-7. View

Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A . Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res. 2000; 6(1):160-5. View

Denmeade S, Sokoll L, Dalrymple S, Rosen D, Gady A, Bruzek D . Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate. 2003; 54(4):249-57. DOI: 10.1002/pros.10199. View

Israeli R, Powell C, Fair W, Heston W . Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993; 53(2):227-30. View

Puhr M, Santer F, Neuwirt H, Marcias G, Hobisch A, Culig Z . SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer. 2010; 17(2):525-38. DOI: 10.1677/ERC-10-0007. View

Arakawa A, Soh S, Chakraborty S, Scardino P, Wheeler T . Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer Prostatic Dis. 2002; 1(1):32-38. DOI: 10.1038/sj.pcan.4500204. View

Anilkumar G, Rajasekaran S, Wang S, Hankinson O, Bander N, Rajasekaran A . Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. 2003; 63(10):2645-8. View

Williams S, Singh P, Isaacs J, Denmeade S . Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. Prostate. 2006; 67(3):312-29. DOI: 10.1002/pros.20531. View

Oesterling J . Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991; 145(5):907-23. DOI: 10.1016/s0022-5347(17)38491-4. View

10.

Sokoloff R, Norton K, Gasior C, Marker K, Grauer L . A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2001; 43(2):150-7. DOI: 10.1002/(sici)1097-0045(20000501)43:2<150::aid-pros10>3.0.co;2-b. View

11.

Carter R, Feldman A, Coyle J . Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A. 1996; 93(2):749-53. PMC: 40126. DOI: 10.1073/pnas.93.2.749. View

12.

Silver D, Pellicer I, Fair W, Heston W, Cordon-Cardo C . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3(1):81-5. View

13.

Hudson D . Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis. 2004; 7(3):188-94. DOI: 10.1038/sj.pcan.4500745. View

14.

van der Heul-Nieuwenhuijsen L, Hendriksen P, van der Kwast T, Jenster G . Gene expression profiling of the human prostate zones. BJU Int. 2006; 98(4):886-97. DOI: 10.1111/j.1464-410X.2006.06427.x. View

15.

Lapidus R, Tiffany C, Isaacs J, Slusher B . Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 2000; 45(4):350-4. DOI: 10.1002/1097-0045(20001201)45:4<350::aid-pros10>3.0.co;2-u. View

16.

Balk S, Ko Y, Bubley G . Biology of prostate-specific antigen. J Clin Oncol. 2003; 21(2):383-91. DOI: 10.1200/JCO.2003.02.083. View

17.

Perner S, Hofer M, Kim R, Shah R, Li H, Moller P . Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007; 38(5):696-701. DOI: 10.1016/j.humpath.2006.11.012. View

18.

Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis M . Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res. 2001; 7(6):1533-8. View

19.

Yao V, Berkman C, Choi J, OKeefe D, Bacich D . Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2009; 70(3):305-16. DOI: 10.1002/pros.21065. View

20.

Tsui P, Rubenstein M, Guinan P . Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol. 2005; 2005(3):287-90. PMC: 1224693. DOI: 10.1155/JBB.2005.287. View